111's (YI) "Sell (E+)" Rating Reaffirmed at Weiss Ratings

Key Points

• The stock of 111 Inc. (NASDAQ:YI) has received a "sell (E+)" rating, which was reaffirmed by Weiss Ratings.
• As of the last trading session, YI stock opened at $6.43 with a market capitalization of $55.56 million and a P/E ratio of -10.05.
• Institutional investors own 21.32% of the company's stock, with notable recent increases in stakes from hedge funds including JPMorgan Chase & Co., which raised its stake by 43,619.9%.

111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (e+)" rating restated by analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

111 Stock Performance

Shares of NASDAQ:YI traded down $0.64 during trading on Friday, reaching $6.43. The stock had a trading volume of 50,650 shares, compared to its average volume of 13,689. The business has a fifty day moving average price of $7.14 and a 200-day moving average price of $7.82. 111 has a 1-year low of $4.14 and a 1-year high of $11.90.

111 (NASDAQ:YI - Get Free Report) last issued its quarterly earnings results on Thursday, June 19th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $486.35 million during the quarter.

Institutional Trading of 111

A number of institutional investors have recently made changes to their positions in YI. JPMorgan Chase & Co. boosted its stake in shares of 111 by 43,619.9% in the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after acquiring an additional 305,339 shares during the last quarter. Deuterium Capital Management LLC acquired a new stake in shares of 111 in the first quarter worth approximately $81,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in 111 during the first quarter worth $92,000. 21.32% of the stock is owned by institutional investors and hedge funds.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.